FIG 6.

BGLF2 induces EBV reactivation in AGS-EBV cells. (A) AGS-EBV-GFP cells stably expressing BGLF2 or luciferase were treated with DMSO or methotrexate (MTX; 50 μg/ml) for 2 days, and then cell lysates were collected and immunoblotted with an antibody to BZLF1, BGLF2, or actin. (B) Supernatants from the cells in panel A were filtered through a 0.45-μm filter and used to infect Raji cells. After 3 days, the cells were lysed and immunoblotted for GFP to determine if virus had been produced from the cells in panel A. (C) AGS-EBV-GFP cells stably expressing BGLF2, BGLF2ΔC, or luciferase were immunoblotted for BZLF1 and actin. (D) Supernatants from the cells in panel C were collected and processed as described for panel B.